Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457618 | 0.82 | SLC18A3 (0.41) | IDO1TDO2SLC6A2SLC6A4GLS | |
| SCHEMBL21437500 | 0.79 | IDO1 (0.44) | IDO1TDO2TAAR1GBA1HTR2A | |
| SCHEMBL7752784 | 0.76 | IDO1 (0.36) | IDO1TDO2SLC6A2SLC6A4GBA1 | |
| SCHEMBL3455735 | 0.76 | IDO1 (0.36) | IDO1TDO2SLC6A2SLC6A4GBA1 | |
| SCHEMBL3455734 | 0.76 | IDO1 (0.36) | IDO1TDO2SLC6A2SLC6A4GBA1 | |
| SCHEMBL3456319 | 0.76 | IDO1 (0.41) | IDO1TDO2SLC6A2SLC6A4GBA1 | |
| SCHEMBL2141555 | 0.76 | IDO1 (0.41) | IDO1TDO2SLC6A2SLC6A4GBA1 | |
| SCHEMBL29427058 | 0.72 | IDO1 (0.47) | IDO1TDO2GBA1ALDH1A1MAPK1 | |
| SCHEMBL248466 | 0.72 | IDO1 (0.47) | IDO1TDO2GBA1ALDH1A1MAPK1 | |
| SCHEMBL7756004 | 0.71 | IDO1 (0.38) | IDO1TDO2GBA1HTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256107-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) | Wyeth LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256107-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) | Wyeth LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1928841-A1 | AMINO-5- Ý4- (DIFLUOROMETHOXY) PHENYL¨-5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038271-A9 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH CORP (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007038271-A9 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH CORP (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007038271-A1 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038271-A1 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | IDO1 4153/4885TDO2 4513/4885BACE1 1/4885 |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | BACE1, BACE2, APP | IDO1 4396/4885TDO2 4607/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.